Abstract：Objective: To observe the changes of serum levels of Th1/Th2 cytokin before and after the treatment of ulcerative colitis (UC). Methods: 58 patients with active UC were selected into UC group while 58 healthy persons as control group. The expression of IL-2、IFN-γ、IL-4、IL-10 in serum were measured at the 3 different time points: before treatment, 3 months and 12 months after treatment. Results: Before treatment, the expression of IFN-γ、IL-10 in serum decreased but IL-4 increased in UC group, with statistical differences (P<0.05). 3 months and 12 months after treatment, the expression of IFN-γ in UC group was lower significantly than control group, but no statistical difference was found in UC group. The expression of IL-4 was higher significantly than control group, especially at the time point of 12 months after treatment (P<0.05). The expression of IL-10 was lower than control group, but it increased significantly at the time point of 12 months after treatment (P<0.05). There was no statistical difference in the expression of IL-2 between the two groups (P>0.05). Conclusion: It was suggested that the expression of IFN-γ decreased and IL-4 increased in serum during active UC, would inhibit the Th1 cells immune response to limit inflammatory process. During the remission of UC, the expression of IL-4 decreased and IL-10 increased would keep the balance of Th1/Th2 cells gradually.
王玮, 谭玉婷, 罗丹, 李启祥, 尹合坤. Th1/Th2细胞因子在初发型溃疡性结肠炎治疗前后的血清水平变化[J]. 河北医学, 2018, 24(1): 167-170.
WANG Wei, TAN Yuting, LUO Dan, et al. The Changes of Serum Levels of Th1/Th2 Cytokines before and after the Treatment of Active Ulcerative Colitis. HeBei Med, 2018, 24(1): 167-170.
[1] Abraham C,Cho JI-I.Inflammatory bowel disease[J].N Engl Med,2009,361(21):2066~2078. [2] Scaldaferri F,Fiocchi C.Inflammatory bowel disease:progress and current concepts of etiopathogenesis[J].Dig Dis,2007,8(4):171~178. [3] Bouguen G,Chevaux JB,Peyrin-Biroulet L.Recent advances in cytokines:therapeutic implications for inflammatory bowel diseases[J].World Gastroenterol,2011,17(5):547~556. [4] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年广州)[J].胃肠病学,2012,17(12):763~781. [5] Boyman O,Sprent J.The role of interleukin 2 during homeostasis and activation of the immune system[J].Nat Rev Immunol,2012,12(3):180~190. [6] Olsen T,Cui G,Goll R,et al.Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis[J].Scand Gastroenterol,2009,44(6):727~735. [7] 邓长生,夏冰.炎症性肠病[M].第2版.人民卫生出版社,2006.152. [8] Lukas M,Drastich P,Konecny M,et a1.Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis[J].Inflamm Bowel Dis,2010,16(7):1180~1186.
2018, Vol. 24 
冀公网安备13080202000677号